InvestorsHub Logo
Followers 26
Posts 1899
Boards Moderated 0
Alias Born 06/15/2007

Re: None

Tuesday, 03/07/2023 1:31:05 PM

Tuesday, March 07, 2023 1:31:05 PM

Post# of 111
Amarin Announces New REDUCE-IT® Data. March 5, 2023.

DUBLIN, Ireland and BRIDGEWATER, N.J., March 05, 2023 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced a new analysis from the VASCEPA/VAZKEPA (icosapent ethyl) cardiovascular outcomes REDUCE-IT study showing the effectiveness of VASCEPA®/VAZKEPA® in patients with recent acute coronary syndrome (<12 months before randomization). This post-hoc analysis showed that icosapent ethyl (IPE) substantially and significantly reduced the risk of first and total ischemic events by 37% and 36% respectively in patients with recent acute coronary syndrome (ACS) without increasing bleeding, supporting early initiation of IPE after ACS. The data were presented at the American College of Cardiology’s 72nd Annual Scientific Session together with the World Heart Federation’s World Congress of Cardiology in New Orleans, LA.

https://healthstockshub.com/news/nasdaq/amrn/amarin-announces-new-reduce-it-data-at-acc-23-wcc-showing-benefit-of-vascepa-vazkepa-icosapent-ethyl-in-high-risk-patients-with-a-recent-acute-coronary-syndrome-event
Bullish
Bullish
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AMRX News